CANCER PREVENTION INITIATIVE INC
Programs
Cancer Prevention Initiative Programs
In 2021, the Cancer Prevention Initiative (CPI) programs have progressed and CPI continues to grow and develop. CPI's research grant recipients have continued to advance us towards understanding and preventing inherited cancers. A newly funded project with Cleveland Clinic seeks to identify proteins uniquely and highly expressed in breast cancer of BRCA1 mutation carriers. Identification of these unique proteins is an important link for developing preventative vaccines. Also newly funded is a project with Memorial Sloan Kettering Cancer Center to generate a robust cellular assay that would allow for the screening of hundreds of compounds to identify determinants of Loss of Heterozygosity (LoH) of BRCA genes. LoH is a major driver in cancer initiation, and discovery of compounds that cause LoH can be key for prevention discoveries. Ongoing projects include Harvard's Beth Israel Deaconess Medical Center where they are working to identify cancer risk predictors in the reproductive epithelium in BRCA mutation carriers. A project at City of Hope is progressing to repurpose a safe, FDA approved anti-parasitic drug that has great promise for reducing breast cancer growth. Repurposing drugs is a safe way to bring therapies to patients quickly. Related to this is a need for ways to evaluate known drugs for new purposes. A team at the University of Toronto is developing a test to screen for drugs that can restore normal BRCA1 function to BRCA1 deficient cells. An international collaboration has co-developed a candidate vaccine for the prevention of triple negative breast cancers in patients who have inherited a BRCA1 mutation. New grants were made in 2021 totaled $480,000. This amount is offset by the return of $264,764 from a 2017 grant where the grantee was not able to complete their contracted project. The grant expenses for 2021 are $480,000 - 264,764 = $215,236.GeographiesNot indicatedDatesJan 1, 2021 – Dec 31, 2021Source990No causes providedNo populations provided–$265.2KCancer Education and Awareness Programs
Education and community engagement programs: As we move closer to our goal of eradicating all cancers through preventative medicines, we believe that educating the public and raising awareness about inherited cancer syndromes will inspire more individuals to take proactive, life-saving preventive measures. One of the goals is to enhance the scientific reach of the organization and raise awareness on cancer prevention to a broader audience of patients, advocates and donors. Thus, regular updates on scientific and medical research advances, recent clinical trials, and interviews with experts in cancer prevention are published on web-based platforms.GeographiesNot indicatedDatesJan 1, 2021 – Dec 31, 2021Source990No causes providedNo populations provided–$5.5KProgram 1 [2024]
In 2024, Cancer Prevention Initiative (CPI) selected new projects to fund. We received more than 50 proposals pertaining to the therapeutic prevention of inherited cancer. In our selection, we expanded our research portfolio beyond BRCA1/2 mutated cancers and one of the new projects studies Lynch Syndrome. We reviewed applications covering all three strategic categories of research: Discovery research that expands the knowledge of early-pre-cancer stages and mechanisms of cancer initiation, development of early detection tests, and the development of chemo and/or immunotherapeutic agents. The volume of proposals indicates both the need for funding in this area and the enthusiasm of the research community to invest their discovery efforts in prevention. Also in 2024, CPI's ongoing research grant recipients have advanced towards greater understanding of preventing inherited cancers. Ongoing projects include Cleveland Clinic, where investigators seek to identify proteins uniquely and highly expressed in breast cancer of BRCA1 mutation carriers. Identification of these unique proteins is an important link for developing preventative vaccines. Also continuing is a project with Memorial Sloan Kettering Cancer Center to generate a robust cellular assay that would allow for the screening of hundreds of compounds to identify determinants of Loss of Heterozygosity (LoH) of BRCA genes. LoH is a major driver in cancer initiation, and discovery of compounds that cause LoH can be key for prevention discoveries. Other ongoing projects include Harvard's Beth Israel Deaconess Medical Center where they are working to identify cancer risk predictors in the reproductive epithelium in BRCA mutation carriers. CPI-funded scientist Dr. Joanne Kotsopoulos and her colleagues at University of Toronto concluded their project, in which they discovered FDA approved drugs that boost patients' sensitivity to PARP inhibitors, which are used in treatment of most cases of inherited ovarian and breast cancer. This work was published in iScience and has the potential to transform treatment of BRCA-mutation driven cancer.GeographiesNot indicatedDatesJan 1, 2024 – Dec 31, 2024Source990No causes providedNo populations provided–$655.9K
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)